AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22571202 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance therapy
Number of subjects: 614
Study 22571202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 614
Study 20821979 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamberin (antioxidant preparation)
Number of subjects: 160
Study 20821979 — intervention group
Group type: COMPARATOR
Intervention: CAF scheme
Number of subjects: 160
Study 20821979 — intervention group
Group type: COMPARATOR
Intervention: AVCFM scheme
Number of subjects: 160
Study 18400281 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet emphasizing plant-based foods and fish, 11 dietary and cooking classes with mindfulness practice
Number of subjects: 36
Study 18400281 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 36
Study 16155034 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.1 microg kg(‐1) min(‐1) (Group R, n=10)
Number of subjects: 20
Study 16155034 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group S, n=10)
Number of subjects: 20
Study 16155034 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 12574731 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified cow's milk formula
Number of subjects: 0
Study 12574731 — intervention group
Group type: COMPARATOR
Intervention: Standard cow's milk formula
Number of subjects: 0
Study 12574731 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-allergen diet
Number of subjects: 0
Study 11217557 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatron 2.5
Number of subjects: 46
Study 8823483 — intervention group
Group type: EXPERIMENTAL
Intervention: 5FU, EPI, MMC with Leucovorin (group B)
Number of subjects: 88
Study 8823483 — intervention group
Group type: COMPARATOR
Intervention: 5FU, EPI, MMC without Leucovorin (group A)
Number of subjects: 88
Study 1563213 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of furosemide (4 mg/hr for 8 hours after an 8 mg loading dose, total dose 40 mg)
Number of subjects: 8
Study 1563213 — intervention group
Group type: COMPARATOR
Intervention: Bolus injection of furosemide (40 mg)
Number of subjects: 8
Study 1563213 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of furosemide
Number of subjects: 8
Study 1563213 — intervention group
Group type: COMPARATOR
Intervention: Bolus injection of furosemide
Number of subjects: 8
Study 3890435 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen (400 mg, intravenous)
Number of subjects: 94
Study 3890435 — intervention group
Group type: COMPARATOR
Intervention: Oxicone (10 mg, intramuscular) combined with papaverine (20 mg)
Number of subjects: 94
Study 3890435 — intervention group
Group type: COMPARATOR
Intervention: Oxicone (10 mg, intramuscular)
Number of subjects: 94
Study 3013766 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol, 80 mg/day plus hydrochlorothiazide 12.5 mg/day
Number of subjects: 13
Study 3013766 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol, 80 mg/day plus hydrochlorothiazide 25 mg/day
Number of subjects: 13
Study 3013766 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol, 80 mg/day plus hydrochlorothiazide 50 mg/day
Number of subjects: 13
Study 3013766 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol, 80 mg/day plus hydrochlorothiazide 12.5 mg/day for 6 weeks
Number of subjects: 13
Study 31222812 — intervention group
Group type: EXPERIMENTAL
Intervention: 3L-Mind-Training programme for 6 weeks
Number of subjects: 126
Study 31222812 — intervention group
Group type: COMPARATOR
Intervention: Regular health promotion activities (Control)
Number of subjects: 126
Study 29885154 — intervention group
Group type: EXPERIMENTAL
Intervention: Seidl method for estimating blood alcohol concentration (eBAC)
Number of subjects: 2282
Study 29885154 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined calculation of eBAC
Number of subjects: 2282
Study 27473311 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Art Therapy (MBAT)
Number of subjects: 24
Study 27473311 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 26246937 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT)
Number of subjects: 136
Study 26246937 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 136
Study 22642891 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice Reaction Time (RT) group
Number of subjects: 0
Study 22642891 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple Reaction Time (RT) group
Number of subjects: 0
Study 22642891 — intervention group
Group type: COMPARATOR
Intervention: Choice RT group in Simple RT condition
Number of subjects: 0
Study 20483019 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolite system (IS)
Number of subjects: 48
Study 20483019 — intervention group
Group type: COMPARATOR
Intervention: Cotton roll isolation (CRI)
Number of subjects: 48
Study 18986062 — intervention group
Group type: EXPERIMENTAL
Intervention: Form information as the main clue
Number of subjects: 0
Study 18986062 — intervention group
Group type: EXPERIMENTAL
Intervention: Space information
Number of subjects: 0
Study 18986062 — intervention group
Group type: EXPERIMENTAL
Intervention: Only colour information
Number of subjects: 0
Study 18986062 — intervention group
Group type: EXPERIMENTAL
Intervention: All three clues (symbol, location, colour) available
Number of subjects: 0
Study 18986062 — intervention group
Group type: EXPERIMENTAL
Intervention: Form information as the main clue in Experiment 2
Number of subjects: 0
Study 18986062 — intervention group
Group type: EXPERIMENTAL
Intervention: No form information used in Experiment 2
Number of subjects: 0
Study 16419569 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT evaluation of regional cerebral blood flow (rCBF)
Number of subjects: 32
Study 12867355 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (SI)
Number of subjects: 12338
Study 12867355 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 12338
Study 11030260 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-centered approach with an average of 14 hours of service for youth and 27 hours for teenagers.
Number of subjects: 1732
Study 11030260 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only 2-5 hours of service.
Number of subjects: 1732
Study 8884536 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal administration of bromocriptine (0.8 mg)
Number of subjects: 20
Study 8884536 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of bromocriptine (2.5 mg)
Number of subjects: 20
Study 1530171 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil during midazolam-narcotic anesthesia
Number of subjects: 20
Study 1530171 — intervention group
Group type: COMPARATOR
Intervention: Halothane-nitrous oxide anesthesia
Number of subjects: 20
Study 3890781 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective shunt
Number of subjects: 55
Study 3890781 — intervention group
Group type: COMPARATOR
Intervention: Nonselective shunt
Number of subjects: 55
Study 30610759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell salvage plus additional WBC depletion filter
Number of subjects: 364
Study 30610759 — intervention group
Group type: COMPARATOR
Intervention: Cell salvage
Number of subjects: 364
Study 30267441 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative cefpodoxime for 7 days
Number of subjects: 150
Study 30267441 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 150
Study 24969964 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly group medical visits
Number of subjects: 200
Study 24969964 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly CRRC individual clinic visits
Number of subjects: 200
Study 24969964 — intervention group
Group type: COMPARATOR
Intervention: Usual care control arm
Number of subjects: 200
Study 22365565 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol infusion
Number of subjects: 10
Study 22365565 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion with remifentanil
Number of subjects: 10
Study 20154079 — intervention group
Group type: EXPERIMENTAL
Intervention: CT‐ANPB (CT scan-guided Abrams needle pleural biopsy)
Number of subjects: 124
Study 20154079 — intervention group
Group type: COMPARATOR
Intervention: Thoracoscopy
Number of subjects: 124
Study 17885351 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 2
Study 17885351 — intervention group
Group type: COMPARATOR
Intervention: Nonpenetrating 'placebo' needle
Number of subjects: 2
Study 16216719 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol diet (PS diet)
Number of subjects: 29
Study 16216719 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate diet (CHO diet)
Number of subjects: 29
Study 16216719 — intervention group
Group type: COMPARATOR
Intervention: New Zealand diet (NZ diet)
Number of subjects: 29
Study 12456232 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (1200 mg/d)
Number of subjects: 2531
Study 12456232 — intervention group
Group type: COMPARATOR
Intervention: Control (matching placebo)
Number of subjects: 2531
Study 11064623 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ropivacaine plus hyaluronidase 300 IU ml-1
Number of subjects: 80
Study 11064623 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine/2% lidocaine plus 50 IU ml-1 hyaluronidase
Number of subjects: 80
Study 8650942 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildly protein restricted diet (0.7 g/kg/day)
Number of subjects: 14
Study 8650942 — intervention group
Group type: COMPARATOR
Intervention: Normal protein diet (1.2 g/kg/day)
Number of subjects: 14
Study 1435170 — intervention group
Group type: EXPERIMENTAL
Intervention: Low impact exercise group
Number of subjects: 15
Study 1435170 — intervention group
Group type: EXPERIMENTAL
Intervention: High impact exercise group
Number of subjects: 15
Study 1435170 — intervention group
Group type: COMPARATOR
Intervention: Control nonexercising group
Number of subjects: 15
Study 3933897 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 0
Study 3933897 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold sodium thiomalate (GST)
Number of subjects: 0
Study 3933897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30433809 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Fragmentation (SF)
Number of subjects: 50
Study 30433809 — intervention group
Group type: COMPARATOR
Intervention: Sleep Deprivation (SD)
Number of subjects: 50
Study 28968794 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD-TDV
Number of subjects: 103
Study 28968794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 25913602 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory public reporting of central line-associated bloodstream infection (CLABSI)
Number of subjects: 17
Study 25913602 — intervention group
Group type: COMPARATOR
Intervention: Hospitals without mandatory public reporting
Number of subjects: 17
Study 23394867 — intervention group
Group type: COMPARATOR
Intervention: Steroid treatment (S group)
Number of subjects: 206
Study 23394867 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with steroid and antiviral agent (S+A group)
Number of subjects: 206
Study 21459795 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation
Number of subjects: 243
Study 21459795 — intervention group
Group type: COMPARATOR
Intervention: Conventional post-remission therapy
Number of subjects: 243
Study 18280811 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-activity genotype (AG, AA) in non-diabetic subjects
Number of subjects: 198
Study 18280811 — intervention group
Group type: COMPARATOR
Intervention: High-activity genotype (G/G) in non-diabetic subjects
Number of subjects: 198
Study 18280811 — intervention group
Group type: COMPARATOR
Intervention: Type 2 DM subjects
Number of subjects: 198
Study 16531708 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy (platinum-based chemotherapy or UFT)
Number of subjects: 0
Study 16531708 — intervention group
Group type: COMPARATOR
Intervention: Postoperative adjuvant therapy
Number of subjects: 0
Study 12937238 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status in patients with low dietary protein intake (DPI < 0.8 g/kg body weight/day) and energy intake (DEI < 25 kcal/kg body weight/day)
Number of subjects: 27
Study 12937238 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional study to increase daily DPI and DEI in LOW group
Number of subjects: 27
Study 12937238 — intervention group
Group type: COMPARATOR
Intervention: Adequate nutrient intake (DPI ≥ 0.8 g/kg body weight/day and DEI ≥ 25 kcal/kg body weight/day) in CON group
Number of subjects: 27
Study 10713234 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5% gel-forming solution (Timoptol-XE(R))
Number of subjects: 0
Study 10713234 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 0
Study 10713234 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study 9333701 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous peritoneal lavage (CPL)
Number of subjects: 0
Study 9333701 — intervention group
Group type: EXPERIMENTAL
Intervention: Open dorsoventral lavage
Number of subjects: 0
Study 9333701 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaparotomy or scheduled reoperation (Etappenlavage)
Number of subjects: 0
Study 9333701 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant medical treatments (TNF alpha and interleukin-1 synthesis inhibitors or antibodies)
Number of subjects: 0
Study 9333701 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurolidine (local and intravenous routes)
Number of subjects: 0
Study 8324332 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 50 mg/kg intravenously
Number of subjects: 12
Study 8324332 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cimetidine)
Number of subjects: 12
Study 3334235 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization using tubigrip support (7-13 days after injury)
Number of subjects: 56
Study 3334235 — intervention group
Group type: COMPARATOR
Intervention: Control group using below-elbow plaster splint (4 weeks)
Number of subjects: 56
Study 29417363 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-messaging program
Number of subjects: 51
Study 29417363 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 28029266 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional hyrax appliance (Group A)
Number of subjects: 54
Study 28029266 — intervention group
Group type: COMPARATOR
Intervention: Hybrid hyrax appliance anchored on mini-implants (Group B)
Number of subjects: 54
Study 26125754 — intervention group
Group type: EXPERIMENTAL
Intervention: Dezocine and butorphanol
Number of subjects: 40
Study 26125754 — intervention group
Group type: COMPARATOR
Intervention: Butorphanol
Number of subjects: 40
Study 24065013 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + Exercise
Number of subjects: 454
Study 24065013 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 454
Study 24065013 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 454
Study 21920204 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone + levobupivacaine + saline (G-M + L)
Number of subjects: 60
Study 21920204 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone + saline (G-M)
Number of subjects: 60
Study 17556007 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training of the elbow flexor muscles in the complete range of motion (group 2)
Number of subjects: 30
Study 17556007 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training of the elbow flexor muscles in the inner range (group 1)
Number of subjects: 30
Study 17556007 — intervention group
Group type: EXPERIMENTAL
Intervention: Both training groups (group 1 and group 2)
Number of subjects: 30
Study 17556007 — intervention group
Group type: COMPARATOR
Intervention: Control arm (dominant arm)
Number of subjects: 30
Study 17056975 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA) with ropivacaine 0.125% and sufentanil 1.0 microg/mL at 14 mL/h; bolus: 5 mL; lockout time: 15 min
Number of subjects: 58
Study 17056975 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCIA) with morphine 2.0 mg/mL; bolus: 3 mg; lockout time: 15 min
Number of subjects: 58
Study 14598938 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin (320 mg/day)
Number of subjects: 28
Study 14598938 — intervention group
Group type: COMPARATOR
Intervention: Trovafloxacin (200 mg/day)
Number of subjects: 28
Study 14598938 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin
Number of subjects: 28
Study 14598938 — intervention group
Group type: COMPARATOR
Intervention: Trovafloxacin
Number of subjects: 28
Study 14598938 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin and Trovafloxacin
Number of subjects: 28
Study 10930765 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterosalpingo‐contrastsonography (HyCoSy)
Number of subjects: 100
Study 10930765 — intervention group
Group type: COMPARATOR
Intervention: Hysterosalpingography (HSG)
Number of subjects: 100
Study 8874573 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular morphine 5 mg
Number of subjects: 61
Study 8874573 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine 5 mg
Number of subjects: 61
Study 8061845 — intervention group
Group type: COMPARATOR
Intervention: 1 mg of spirapril once daily
Number of subjects: 171
Study 8061845 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg of spirapril once daily
Number of subjects: 171
Study 8061845 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg of spirapril once daily
Number of subjects: 171
Study 8061845 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 mg of spirapril once daily
Number of subjects: 171
Study 2647050 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of cefoxitin before operation
Number of subjects: 1735
Study 2647050 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis mentioned)
Number of subjects: 1735
Study 30565342 — intervention group
Group type: COMPARATOR
Intervention: Simulated TEAS combined with sertraline (group A)
Number of subjects: 240
Study 30565342 — intervention group
Group type: COMPARATOR
Intervention: Simulated TEAS combined with CBT (group B)
Number of subjects: 240
Study 30565342 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TEAS combined with CBT (group C)
Number of subjects: 240
Study 30565342 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TEAS combined with CBT plus sertraline (group D)
Number of subjects: 240
Study 28527821 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine buffered with sodium bicarbonate (9:1 ratio)
Number of subjects: 85
Study 28527821 — intervention group
Group type: COMPARATOR
Intervention: 1% lidocaine alone (control group)
Number of subjects: 85
Study 25306231 — intervention group
Group type: EXPERIMENTAL
Intervention: burst TENS
Number of subjects: 112
Study 25306231 — intervention group
Group type: EXPERIMENTAL
Intervention: cryotherapy
Number of subjects: 112
Study 25306231 — intervention group
Group type: EXPERIMENTAL
Intervention: cryotherapy in combination with burst TENS
Number of subjects: 112
Study 25306231 — intervention group
Group type: EXPERIMENTAL
Intervention: cryotherapy in combination with conventional TENS
Number of subjects: 112
Study 25306231 — intervention group
Group type: EXPERIMENTAL
Intervention: conventional TENS
Number of subjects: 112
Study 25306231 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo TENS
Number of subjects: 112
Study 25306231 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 112
Study 23777380 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (Nordic curl, forward lunges on a Bosu balance trainer, eccentric single leg dead lifts)
Number of subjects: 20
Study 23777380 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 23237643 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological Inoculation (PI)
Number of subjects: 22
Study 23237643 — intervention group
Group type: COMPARATOR
Intervention: Health Education (Control)
Number of subjects: 22
Study 23237643 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study 19681881 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs published in 2006
Number of subjects: 98
Study 19681881 — intervention group
Group type: COMPARATOR
Intervention: RCTs published in 1997
Number of subjects: 98
Study 17512147 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet A (swelling/disintegration-type matrix tablet with hydrophobic wax and hydrophilic polymer granules)
Number of subjects: 0
Study 17512147 — intervention group
Group type: COMPARATOR
Intervention: Tablet B (matrix tablet consisting of hydrophilic polymer granules)
Number of subjects: 0
Study 17512147 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet A
Number of subjects: 0
Study 17512147 — intervention group
Group type: COMPARATOR
Intervention: Tablet B
Number of subjects: 0
Study 15448514 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 83
Study 15448514 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 83
Study 15448514 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 83
Study 15448514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 11504980 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART responders
Number of subjects: 44
Study 11504980 — intervention group
Group type: COMPARATOR
Intervention: HAART non-responders
Number of subjects: 44
Study 11504980 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with virological or immunological response
Number of subjects: 44
Study 11504980 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunological response, higher RDI, CR to chemotherapy
Number of subjects: 44
Study 9676069 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer Antidepressants (NAs)
Number of subjects: 0
Study 9676069 — intervention group
Group type: COMPARATOR
Intervention: Older Antidepressants (OAs) - TCA group
Number of subjects: 0